BIOLASE, INC: Nasdaq/NYSE listing notice — BIOLASE receives Nasdaq delisting notice for bid price non-compliance; hearing requested

BIOLASE, INC

Received Nasdaq Staff Letter on April 15, 2024, for failing $1.00 minimum bid price for 30 consecutive business days through March 1, 2024.
Ineligible for automatic compliance period due to prior panel monitor (Aug 14, 2023) and reverse stock splits exceeding 250:1 cumulative over two years.
Company will request a hearing before Nasdaq Hearings Panel; request automatically stays suspension/delisting pending hearing and panel decision.
Panel may grant extension of compliance period up to October 14, 2024. Prior letter of March 4, 2024 was issued in error.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 15, 2024, BIOLASE, Inc. (the “Company”) received a staff determination letter (the “Staff Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC notifying the Company that, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”), its securities could be subject to suspension from trading on The Nasdaq Capital Market for failure to meet the $1.00 minimum closing bid price requirement for the 30 consecutive business days from January 19 through March 1, 2024, as required by Listing Rule 5550(a)(2), and that the Com

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-24-046010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.